We studied changes in stroke prevention in 2000 increased with time (28% to 72%) (p<0.001), but did not increase for asymptomatic vascular disease, ischaemic stroke patients using prospectively collected data from an incident stroke register over 3 despite risk factors being present. The proportion of patients receiving antihypertensive treatment for years. Patients were divided into those with risk factors but no previous history of a vascular event symptomatic vascular disease was unchanged with time (66% to 64%) but there was a significant (asymptomatic vascular disease) and those with risk factors and a previous history of stroke or TIAs, ischincrease in the number of patients receiving antihypertensive treatment for asymptomatic vascular disaemic heart disease, angina, myocardial infarction or peripheral vascular disease (symptomatic vascular ease (28% to 44%) (p<0.05). The proportion of patients with atrial fibrillation receiving antithromdisease). Time trends were analysed for the use of aspirin, management of hypertension and atrial fibrilbotic treatment did not increase for asymptomatic vascular disease (23% to 21%) (p=0.54) but did lation prior to the presenting episode. Median age of those with known risk factors included in the study increase for symptomatic vascular disease (19.5% to 37%) ( p<0.01) over 3 years. The use of warfarin in was 75 years (range 44-99 years); 60% were women. Year-by-year analysis showed no differences in demoatrial fibrillation increased both in the case of asymptomatic (4.5% to 42%) (p<0.01) and symptomatic graphy, stroke characteristics or vascular risk profile. The use of aspirin for symptomatic vascular disease vascular disease (12.5% to 33.0%) (p<0.01).
Introduction
Several well-designed randomized controlled studies have been targeted towards health education, screening and intervention in the last few years.5 have shown that identification and treatment of vascular risk factors reduces the incidence of There are fears that research evidence or health initiatives may fail to change clinical practice and stroke. [1] [2] [3] [4] The most relevant interventions in this context are control of hypertension, use of aspirin management of cardiovascular risk factors in clinical care may remain sub-optimal.6 Past studies have for primary and secondary prophylaxis, and anticoagulation in patients with atrial fibrillation. There now shown that preventive care is inadequate in patients at risk, even after a vascular event has taken place.7-10 is overwhelming research evidence to support aggressive management of these risk factors, which However, there is optimism that a co-ordinated strategy aimed at increasing awareness of stroke as has been widely publicized in medical and nonmedical literature. In addition, management of vascua major health issue may result in improvements, both in primary and in secondary prevention.11 The lar risk factors has been prioritized in national healthcare programmes, and significant resources objective of this study was to see if this optimism was justified by studying year-on-year changes in another medical condition (ischaemic heart disease etc.), was not recorded as antihypertensive. primary and secondary prevention (treatment of atrial fibrillation, hypertension and the use of antithromResults were analyses using Minitab v8.2. Parametric data were analysed with the t test for botic agents) for stroke in a large sub-urban population in south-east England. unpaired data. Dichotomous variables were analysed using the two-tailed x2 test for significance at the 5% level.
Methods
We analysed incident stroke register data for a population of 550 000 collected prospectively for 3
Results years starting January 1994. The stroke register included all patients admitted to hospital with a The median age of patients included in the study was 75 years (range 44-99 years) and 60% were diagnosis of stroke, regardless of location. First-ever and recurrent strokes were included. All admissions females (Table 1) . Year-by-year analysis showed that there were no significant differences in the demoto hospital were screened on a daily basis, and those with a presumptive diagnosis of stroke were assessed graphy, stroke characteristics or vascular risk profile of patients with time (Table 1) . by a stroke specialist to confirm the diagnosis. Case ascertainment was undertaken by comparisons with Symptomatic vascular disease (TIAs, stroke, angina, myocardial infarction or peripheral vascular the hospital activity analysis databases. The WHO definition of stroke was used, and initial diagnosis disease) was present in 1139 (57%) patients prior to the presenting episode. Aspirin for prevention of was based on history and clinical examination by specialists in stroke. The diagnosis and pathology of vascular events (myocardial infarction, stroke or peripheral occlusion) was used more frequently in stroke was confirmed by CT scanning in 89% of the patients included in the study. Data were collected patients with symptomatic vascular disease than in asymptomatic patients (54.6% vs. 16.8%; meticulously on patient and stroke characteristics, and frequency of risk factors from patients, relatives, p<0.0001) despite no differences in risk factor prevalence. The dose of aspirin varied between general practitioners and hospital sources, and were cross-validated for completeness and accuracy. A 75 mg and 300 mg, with most patients being on lower doses (75 or 150 mg). Year-by-year analysis comprehensive review of management prior to the stroke was undertaken using the sources described showed a significant increase in the use of aspirin in symptomatic vascular disease (28% to 72%; above to collect information on known risk factors and their management before the presenting episode.
p<0.001), but a similar trend was not seen in the use of aspirin for asymptomatic vascular disease Special care was taken in collecting information about the use of aspirin, because low-dose aspirin is ( Table 2) . Of the 882 known hypertensives, 486 (55%) were often not regarded as medication or may be used without prescription. In addition, the patient (wherreceiving antihypertensive treatment prior to their stroke. A significantly greater proportion of patients ever possible) or their families were questioned directly about compliance with treatment.
with previous vascular events were receiving antihypertensive treatment compared with patients known All patients with a diagnosis of ischaemic stroke on the register were divided into two groups: those to have hypertension but no vascular events (66% vs. 36%; p<0.001). The proportion of patients no previous history of a vascular event (asymptomatic vascular disease) and those with a previous history receiving antihypertensive treatment in the presence of symptomatic vascular disease did not change with of stroke or TIAs, ischaemic heart disease, angina, myocardial infarction or peripheral vascular disease time (Table 2 ). However, there was a significant increase in the number of patients receiving antihy-(symptomatic vascular disease). The prevalence of known risk factors was recorded in both groups.
pertensive treatment in the presence of asymptomatic vascular disease (28% to 44%) (p<0.05). Time trends were analysed for the use of aspirin and the management of hypertension, diabetes mellitus
The proportion of patients with atrial fibrillation being anticoagulated rose from 4.5% in the first year and atrial fibrillation prior to the presenting episode. The criteria for identification these risk factors were to 42% (p<0.01) in the third, with increased use following a stroke of 12.5% to 33.0% (p<0.01) in based on accepted recommendations in literature.12-14 The use of medication for the treatment of the third year. The proportion receiving aspirin for atrial fibrillation remained constant (23% to 21%) hypertension was confirmed from the history and by directly asking the patient. Medication that had an (p=0.45), but following a stroke there was increased usage (19.5% to 37%) (p<0.01) by the third year. antihypertensive effect but was being used to treat 1994-1995. ** p<0.01, 1994-1996. care physicians resulting from published evidence, Discussion availability of peer-approved guidelines and prioritizIn contrast to previous studies showing poor impleation of cardiovascular risk prevention in the national mentation of prevention in stroke,7-10 this study strategy for health.11,18 shows that preventive measures are undertaken in a
The limitations of indirect assessment of stroke large proportion of patients at risk prior to the prevention based on incident stroke need to be presenting episode. This appears to be particularly acknowledged. The denominator here is the number true for patients with a prior history of vascular of patients suffering a critical event and presenting events requiring secondary prevention, in whom the to the stroke service rather those with vascular risk, effectiveness and benefits of such interventions are giving rise to the possibility of under or overestimalikely to be greater. The study also shows an encourting the proportion of patients being managed. In aging trend in the management of asymptomatic addition, this study addressed the basic question of vascular disease, with increasing recognition and estimating the proportion of stroke patients who management of risk factors, especially hypertension received any treatment for vascular risk factors prior and atrial fibrillation.
to ictus, regardless of appropriateness or quality of The improvements in secondary prevention may control. Subsequent studies have shown this to be be due to several reasons. It is likely that vascular an issue.19 More refined information can only be events alert physicians to actively screen for risk provided by prospective longitudinal studies in large factors, and that the benefits of active management numbers of patients with vascular risk managed in are perceived as being greater in this group. Specialist several settings. Such studies are expensive, labourinvolvement is likely to be greater in this group, intensive and difficult to undertake because of logistic resulting in improved screening and aggressive manconsiderations of multiplicity of sites, coordination agement of risk factors.6,15 In addition, patients who of data sources and duration of follow-up. On the have experienced a vascular event are known to be other hand, the need for this information cannot be more willing to seek help and comply with prevenignored and there are pressures to develop alternative tion programmes.16,17 On the other hand, the positive methods to monitor prevention, which will be simtrends in the management of vascular disease reflect a change in perceptions and practice of primarypler but complementary to the very expensive pro-
